Suppliers / Livzon New North River Pharmaceutical

Livzon New North River Pharmaceutical

China Updated 9 July 2026

Livzon New North River Pharmaceutical is an API and finished-dose manufacturer based in China. It holds one active US drug master file across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 20 December 2024 as VAI.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
3
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 20 December 2024 VAI US FDA
  • 23 May 2019 NAI US FDA
  • 6 November 2015 NAI US FDA
  • 22 March 2013 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3005619530

What they file, and where

Molecule Regulators Docs
Moxidectin US FDA 1
Tobramycin SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Semaglutide finished dose Tobramycin API

Filings and GMP by regulator

Regulator Filings GMP certificates
ARCSA (EC) 3 None
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Livzon New North River Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 20 December 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates